• Skip to main content
  • Skip to footer
  • Careers
  • Contact

Abzyme Therapeutic

Impacting the research, diagnosis and treatment of human diseases through our novel antibody discovery and optimization platform

  • Services
    • Services Overview
    • Discovery
    • Engineering and Optimization
    • Plug and Play Platform
  • Technology
    • Overview
    • SDALibTM Ab Generation
    • SDALibTM Ab Optimization
    • Abz2TM Bispecific
  • Company
    • About
    • Who We Are
    • Partnerships
    • Management Team
    • For Investors
  • Preclinical Pipeline
    • Overview
    • Assets for Immuno-oncology
    • Assets for Other Indications
  • Media and Publications
    • Press Releases
    • Events & Presentations
    • Publications by Abzyme Scientists

Main Content

Slide In vivo antigen-directed antibody affinity maturation: Mimicking mammalian antibody diversification & affinity maturation processes. READ MORE >> Slide Novel triple-mode platform for in vivo antibody maturation, surface display and secretion. READ MORE >> Slide Single domain antibody: ideal building block to generate multi-specific antibody molecules. READ MORE>> Slide Abz2 bispecifics: Well-expressing multi-function full-length antibody with a completely normal IgG structure. READ MORE >> Slide Eukaryotic-based in vitro selection system: Filters for well-expressing and manufacturable antibody candidates. READ MORE>> Slide Ideal platform for generation of antibodies against non-immunogenic and cell surface antigens. READ MORE>> Slide Advanced optimization capabilities to produce conditionally-active antibodies. READ MORE>> Impacting the treatment of human disease through domain antibody technologies

Footer

© Abzyme Therapeutics, LLC. All Rights Reserved.

321 Jones Blvd, Royersford, PA 19468
610-990-7531 | [email protected]